Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose
…, E Yoshikawa, H Okada, M Takekuma… - European journal of …, 2002 - Springer
This study was designed to assess the value of whole-body positron emission tomography (PET)
using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) for the diagnosis of recurrent …
using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) for the diagnosis of recurrent …
A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: analysis of 37 cases
…, Y Sato, T Iwata, Y Hirashima, M Takekuma… - Gynecologic …, 2017 - Elsevier
Objective High-grade neuroendocrine carcinoma of uterine cervix (HGNCUC) has been
recognized as a highly malignant tumor. Therapeutic strategy specific to neuroendocrine (NE) …
recognized as a highly malignant tumor. Therapeutic strategy specific to neuroendocrine (NE) …
Imaging of gynecologic tumors: comparison of 11C-choline PET with 18F-FDG PET
…, E Yoshikawa, F Nakamura, M Takekuma… - Journal of Nuclear …, 2003 - Soc Nuclear Med
This study was designed to compare the value of PET using 11 C-choline with that of PET
using 18 F-FDG for the diagnosis of gynecologic tumors. Methods: We examined 21 patients, …
using 18 F-FDG for the diagnosis of gynecologic tumors. Methods: We examined 21 patients, …
The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I–II cervical cancer: A review
M Takekuma, Y Kasamatsu, N Kado… - Journal of Obstetrics …, 2017 - Wiley Online Library
The treatment for most patients with early‐stage cervical cancer involves radical hysterectomy
and pelvic lymph node dissection, and indications for postoperative adjuvant therapy have …
and pelvic lymph node dissection, and indications for postoperative adjuvant therapy have …
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
…, J Martínez-García, G Villacampa, M Takekuma… - The Lancet, 2024 - thelancet.com
Background The GOG240 trial established bevacizumab with chemotherapy as standard
first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–…
first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–…
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based …
…, S Kuji, A Tanaka, N Takahashi, M Takekuma… - Supportive care in …, 2016 - Springer
Purpose Olanzapine is effective in chemotherapy-induced nausea and vomiting (CINV). In
patients receiving highly emetogenic chemotherapy (HEC), its efficacy was reported as …
patients receiving highly emetogenic chemotherapy (HEC), its efficacy was reported as …
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826
…, A Okamoto, Y Aoki, H Itamochi, M Takekuma… - Cancer …, 2022 - Wiley Online Library
Pembrolizumab plus chemotherapy with or without bevacizumab demonstrated prolonged
progression‐free survival (PFS) and overall survival (OS) versus chemotherapy in patients …
progression‐free survival (PFS) and overall survival (OS) versus chemotherapy in patients …
Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma
…, S Yanai, M Nishimura, T Nagano, M Takekuma… - Gynecologic …, 2017 - Elsevier
Background To examine recurrence patterns in women with stage I uterine carcinosarcoma (UCS)
stratified by adjuvant therapy pattern. Methods We examined 443 cases of stage I …
stratified by adjuvant therapy pattern. Methods We examined 443 cases of stage I …
Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer
M Takekuma, M Maeda, T Ozawa, K Yasumi… - International journal of …, 2005 - Springer
Background Recurrent ovarian cancer is refractory and resistant to treatment in most patients,
and no effective treatment for it has been established. Starting a treatment when tumors …
and no effective treatment for it has been established. Starting a treatment when tumors …
Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy
M Takekuma, Y Kasamatsu, N Kado, S Kuji… - International journal of …, 2016 - Springer
Background The aims of this study were to evaluate the efficacy and toxicity of chemotherapy
(CT) compared with concurrent chemoradiotherapy (CCRT) after radical hysterectomy and …
(CT) compared with concurrent chemoradiotherapy (CCRT) after radical hysterectomy and …